{"filings":[{"id":746358,"accession_number":"0001178253-26-000017","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-05-29T20:01:37+00:00","items":["5.03","9.01"],"status":"ready","headline":"SCYNEXIS effects 1:8 reverse stock split; authorized shares cut to 18.75M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Effective May 29, 2026, every 8 outstanding shares converted into 1 share; par value stays $0.001.","Authorized common shares reduced from 150,000,000 to 18,750,000.","No fractional shares issued; eligible stockholders receive cash in lieu.","Split-adjusted trading on Nasdaq begins June 1, 2026 under ticker SCYX; new CUSIP 811292309.","Reverse split also adjusts stock options, RSUs, and warrants with proportional exercise price changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609918,"accession_number":"0001178253-26-000014","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-05-22T20:20:18+00:00","items":["5.07","8.01"],"status":"ready","headline":"SCYNEXIS stockholders approve 1-for-8 reverse stock split; effective May 29","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved at 1:8 ratio; authorized shares reduced from 150M to 18.75M.","Special meeting results: 44.8 million votes for, 6.7 million against, 0.1 million abstained.","Effective May 29, 2026; trading on Nasdaq on split-adjusted basis starts June 1, 2026.","No fractional shares issued; cash payment in lieu for fractional interests.","New CUSIP 811292 309; ticker symbol SCYX unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91697,"accession_number":"0001178253-26-000009","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Steven C. Gilman to retire from SCYNEXIS Board at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven C. Gilman notified SCYNEXIS Board on April 16, 2026 of intent to retire and not stand for reelection.","Gilman's term ends at the 2026 annual meeting; he remains Compensation Committee Chair and Nominating & Governance member until then.","Resignation not due to any disagreement with Company's operations, policies, strategy, management, or Board.","Management and Board thanked Gilman for his years of service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101949,"accession_number":"0001193125-26-134476","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SCYNEXIS discusses asset acquisition in corporate update call","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Conference call held on March 31, 2026 covering an asset acquisition transaction.","Slide presentation filed as Exhibit 99.1; no financial terms disclosed in this 8-K.","Company's deck highlights focus on severe rare disease solutions.","No specific revenue, earnings, or closing timeline provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101948,"accession_number":"0001193125-26-133259","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"SCYNEXIS raises ~$40M in private placement; extends cash runway into mid-2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$40M from sale of 34.75M shares and 8.75M pre-funded warrants at $0.92 per unit; up to $52.2M additional if warrants exercised.","Common warrants exercisable at $1.20 per share, subject to stockholder approval; expire 5 years or 30 days after Week 48 data for SCY-770 in ADPKD.","CEO David Angulo purchased 108,695 shares and warrants; proceeds to be used for working capital and general corporate purposes.","Cash runway extended into mid-2029 based on current plans, including anticipated net proceeds from the private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101947,"accession_number":"0001193125-26-133250","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"SCYNEXIS acquires PXL-770 (SCY-770) from Poxel for $8M upfront, up to $188M total","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset includes direct AMPK activator PXL-770, now SCY-770, for ADPKD, with Orphan Drug Designation from FDA.","Upfront payment of $8M; potential development milestones up to $8M and commercial milestones up to $180M.","Phase 2 proof-of-concept study in ADPKD expected to start Q4 2026; early efficacy readout anticipated H2 2027.","SCY-770 has been evaluated in eight clinical trials with a favorable safety profile and targets underlying ADPKD drivers.","SCYNEXIS plans to host a conference call on March 31, 2026 at 8:30 AM ET to discuss the acquisition and corporate update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118280,"accession_number":"0001178253-25-000006","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"SCYNEXIS resolves MARIO study dispute with GSK, receives $22M payment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Binding MOU terminates Phase 3 MARIO trial for invasive candidiasis; SCYNEXIS gets $22M from GSK.","Additional $2.3M payment from GSK for wind-down and termination activities.","SCYNEXIS will transfer BREXAFEMME NDA to GSK by end of 2025; GSK plans FDA interactions in 2026 for VVC/rVVC relaunch.","Milestones and royalties for VVC and rVVC indications remain unchanged under the exclusive license agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134730,"accession_number":"0000950170-25-092176","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SCYNEXIS stockholders re-elect all seven directors, ratify Deloitte, approve say-on-pay at 2025 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with >13M votes for each; broker non-votes ~12.5M.","Ratification of Deloitte & Touche as auditor for FY 2025 passed: 25.5M for, 0.8M against.","Advisory vote on executive compensation approved: 12.4M for, 1.4M against, 0.7M abstain.","Annual meeting held June 25, 2025; all proposals passed as recommended by the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151635,"accession_number":"0000950170-25-090374","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"SCYNEXIS receives Nasdaq bid price deficiency notice; has until Dec 17 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on June 20, 2025, for bid price <$1 for 30 consecutive business days.","Has 180 calendar days until December 17, 2025, to regain compliance with minimum bid price.","May transfer to Nasdaq Capital Market for additional 180-day compliance period if needed.","Will evaluate options including potential reverse stock split to cure deficiency.","No assurance of regaining compliance; could face delisting if not cured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187473,"accession_number":"0000950170-24-122291","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SCYNEXIS enters $50M at-the-market equity facility with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with Cantor allows sale of up to $50M of common stock at SCYNEXIS's option.","Compensation to agent is 3% of gross sale proceeds under ATM offering.","Prior agreements with Cantor and Ladenburg terminated; $3.8M had been sold under those.","Offering is through effective S-3 registration statement filed Nov 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203983,"accession_number":"0000950170-24-104918","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SCYNEXIS updates corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed 8-K on Sept 10, 2024 to announce updated investor slide deck.","Exhibit 99.1 is the revised Corporate Presentation dated September 2024.","No specific financial or pipeline milestones were referenced in the filing or exhibit text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220648,"accession_number":"0000950170-24-075321","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SCYNEXIS stockholders elect all seven director nominees, approve equity plan and auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with 93.6%-96.7% of votes cast in favor.","Ratification of Deloitte & Touche as auditor for FY 2024 passed with 97.0% of votes cast.","Advisory vote on executive compensation approved with 87.1% of votes cast (excluding broker non-votes).","SCYNEXIS 2024 Equity Incentive Plan approved with 83.4% of votes cast (excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}